Navigation Links
Genzyme Announces Presentation of New Positive Data on Carticel(R)
Date:3/10/2008

d not undergone a marrow stimulation technique prior to treatment with ACI.

"The data show that in this patient population marrow stimulation techniques like microfracture are not benign and can compromise a patient's ability to benefit from a subsequent treatment with ACI, effectively limiting their future treatment options," said Tom Minas, MD, an internationally renowned orthopaedic surgeon for his extensive work in the field of Cartilage Repair and principal investigator in this study. "Orthopaedic surgeons should reconsider using marrow stimulation techniques as first-line treatment for patients with larger chondral lesions. These techniques should be reserved for patients with smaller defects, in younger patients, where a good result is more predictable."

A Unique Cell Therapy

More than 14,000 patients in the United States have had Carticel implants. Carticel is used by orthopaedic surgeons to treat patients who have clinically significant articular cartilage lesions on the thigh bone part of the knee caused by acute or repetitive trauma that have not responded to a prior cartilage repair procedure. Carticel should only be used in conjunction with debridement, placement of a periosteal flap and rehabilitation. The independent contributions of the autologous cultured chondrocytes and other components of the therapy to outcome are unknown. Carticel employs a unique process to grow a patient's own cartilage cells for implantation to correct certain types of damage. The treatment starts when an orthopaedic surgeon trained in the use of Carticel provides Genzyme with a biopsy of healthy cartilage taken from a patient's knee in an arthroscopic procedure. Technicians at Genzyme's cell culture laboratory in Cambridge, MA, use proprietary methods to grow millions of cells from this biopsy. The cells are then delivered to the hospital, where the surgeon implants them into the patient's knee defect in a surgical procedure.

Carticel was the fir
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "12th ... and Production" report to their offering. ... of Biopharmaceutical Manufacturing Capacity and Production is the ... manufacturing organizations, current and projected future capacity and ...
(Date:8/28/2015)... Patterson Medical, formerly the medical business ... is now an independent company with today,s completion ... by Madison Dearborn Partners (MDP).  ... transition period before rebranding as the world,s leading ...  With the focused resources and expertise of MDP, ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Latanoprost Market, ... Developed by Pharmacia & Upjohn in 1995, latanoprost ... reduces intraocular pressure. As the first pressure- lowering ... name of Xalatan) entered China ...
Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3China Latanoprost Market Investigation Report 2015-2019 2
... Pharmaceutical,Inc.,s (OTC Bulletin Board: NURX) next-generation rexinoid agonist,NRX4204, ... tumors and,lowered the total tumor volume in mouse ... paper published in Clinical Cancer Research (2007;,Vol. 13, ... showed that NRX4204 caused marked tumor,regression in all ...
... provide best science available, BETHESDA, Md., March ... methodology for CNS clinical trials, United BioSource,Corporation (UBC) ... for,Data Quality. This Advisory Board was established to ... quality and outcomes in CNS trials that,rely on ...
Cached Medicine Technology:Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports 2Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports 3UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 2UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 3
(Date:8/31/2015)... Florida (PRWEB) , ... August 31, 2015 , ... ... is excited to establish its first Digital Hub in North America, now open ... before selecting Florida,” stated Founder and CEO John Campbell. “Jacksonville’s lifestyle, waterways and ...
(Date:8/31/2015)... ... August 31, 2015 , ... Intellitec Solutions announced they ... bringing on board their 8th new staff member in 2015. With the potential for ... firm. Intellitec Solutions supports Microsoft Dynamics GP, Dynamics SL, Dynamics CRM and Intacct, and ...
(Date:8/31/2015)... ... 31, 2015 , ... NSF International, an independent global organization ... sciences and consumer goods industries, has recognized Clean Water Systems & Stores Inc ... Manganese Dioxide. , Developed by a team of scientists and industry experts NSF/ANSI ...
(Date:8/31/2015)... ... August 31, 2015 , ... All birth control methods work best if ... failure rates among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages with ... have their vasectomy done because they are afraid of complications. , One Stop ...
(Date:8/31/2015)... ... August 31, 2015 , ... Adult & Pediatric Dermatology in ... dermatology patients of the treatments and services available to help them. , ... innovative and ‘responsive design’ that allows visitors to view the website seamlessly on any ...
Breaking Medicine News(10 mins):Health News:Global Digital Opens USA Digital Agency Hub 2Health News:Intellitec Solutions Achieves Record Pace for New Hiring 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 2Health News:NSF International Has Recognized Clean Water Systems & Stores Inc Facility 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3
... As ... be welcoming world leaders to the David L. Lawrence Convention Center, the largest "green" ... Design) certification. , ... Pittsburgh, Pa. (PRWEB) September 24, 2009 -- As the industry leader in automatic door ...
... , , , SEATTLE, ... launched the Living Proof Project: U.S. Investments in Global Health ... success of the U.S. government,s efforts to improve health around ... Project will show that U.S.-supported initiatives to fight malaria, AIDS, ...
... , , , INDIANAPOLIS, ... District of Indiana today upheld Eli Lilly and Company,s (NYSE: ... tablets). In the case of Eli Lilly and Company ... favor of Lilly on all accounts for these method-of-use patents, ...
... , , , ... Northern Ireland, moderated by President Clinton, featured Peter Robinson, first ... Northern Ireland Executive; Declan Kelly, economic envoy to Northern Ireland, ... Northern Ireland; and Micheal Martin, Minster of Foreign ...
... Sept. 23 Allowing age adjustments more restrictive than 5 to ... in the individual insurance market, making coverage unaffordable for many according ... Cross and Blue Shield Association (BCBSA) released today new data, prepared ... that a 2 to 1 age rating ratio would increase premiums ...
... NEW YORK, Sept. 23 The Michael J. ... to successfully translate neurotrophic factor advances from pre-clinical and early-phase ... The funding will be awarded under a new Directed ... , , The Foundation,s intention is to ...
Cached Medicine News:Health News:BEA Opens the Doors to the World at G20 Summit 2Health News:BEA Opens the Doors to the World at G20 Summit 3Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 2Health News:Gates Foundation Launches Campaign to Highlight Success of U.S. Global Health Investments 3Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 2Health News:U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 2Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 3Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 4Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 5Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 6Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 7Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 8Health News:President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development 9Health News:Analysis Shows Narrow Age Rating Would Raise Premiums by Nearly 50 Percent, Causing Many Young and Healthy to Forgo Coverage 2Health News:Michael J. Fox Foundation Commits Up to $5 Million to Help Advance Neurotrophic Factors 'From Promise to Reality' As Parkinson's Treatment 2
... this is the universal lithotripter for ... urinary and biliary treatment. The system ... with other applications including cystoscopy, ureteronoscopy, ... system comprises the height adjustable urologist' ...
... This therapeutic system ... the patient in mind. ... surgery and ongoing therapy, ... low-risk and effective therapy. ...
... Reach a new dimension! That of the ... unequalled performance and ease of use. Enjoy ... electroconductive shock wave technology coupled with the ... system. Manage the patient treatment, X-ray and ...
... The MINILITH SL1 developed by STORZ ... of extensive experience in the field of ... of the specific requirements to be met ... therapy, as has been outlined above. The ...
Medicine Products: